Clinical trialCLINICALTRIALSYesterday
Researchers are testing a new drug called BH-30643 for advanced lung cancer patients whose tumors have specific genetic mutations (EGFR or HER2). The study will first figure out the right dose and watch for side effects, then test how well the drug works against the cancer. About 266 patients will participate across multiple hospitals.
WHY IT MATTERSThis trial is now actively recruiting patients with EGFR and/or HER2-mutated advanced NSCLC — if you have this genetic profile and have exhausted standard treatments, you may be eligible to access a potentially new treatment option.
Drug approvalOPENFDAYesterday
The FDA has approved a new drug made by Merck Sharp and Dohme LLC. However, the specific name of the drug and the disease it treats are not listed in this announcement. Patients and doctors will need to find more details from official FDA sources to learn what condition this drug is for and whether it might help them.
WHY IT MATTERSWithout knowing the specific drug name and indication, we cannot determine the relevance to any particular patient population — this announcement lacks critical details needed to assess impact.
Clinical trialRSS3 days ago
A new drug called masitinib helped ALS patients live longer than expected. In a clinical trial, over 40% of patients treated with masitinib survived for at least 5 years from when their disease started. This is much better than the typical outcome, where fewer than 25% of ALS patients usually live that long.
WHY IT MATTERSIf masitinib gains approval, ALS patients may have access to a treatment that could significantly extend their survival time compared to current standard care.